Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity.

Clin Immunol Immunopathol. 1996 Nov;81(2):182-90. Unique Identifier : AIDSLINE MED/97064131
Black KP; Cummins JE Jr; Jackson S; Department of Microbiology, University of Alabama at Birmingham,; 35294-2170, USA.

Abstract: The potential function of IgA anti-HIV antibodies in mediation of antibody-dependent cellular cytotoxicity (ADCC) was investigated in this study. Serum IgA isolated from HIV-seropositive subjects in stage B3 or C3 and from healthy seronegative individuals was compared to IgG and whole serum for the ability to mediate ADCC. Peripheral blood mononuclear cells isolated from uninfected donors were used as effectors against CEM-NKr cells chronically infected with the HTLV-IIIB strain of HIV-1. Whole sera, isolated IgA, and IgG from both groups of seropositive individuals were capable of significant ADCC lysis against infected CEM-NKr cells compared to identical preparations from seronegative individuals. In comparing ADCC activity between the two seropositive groups, IgG mediated higher mean ADCC levels in the C3 group at the two highest concentrations of antibody assayed (P < 0.03), whereas IgA mediated the highest mean ADCC levels in the B3 group at all concentrations. Secretory IgA (S-IgA) isolated from colostrum of HIV-infected women was also examined for ADCC capabilities against infected CEM-NKr cells. Significant differences were observed between ADCC mediated by S-IgA from seropositive mothers compared to seronegative mothers (P < 0.04), but the amount of lysis detected was not as great as that seen with serum IgA. The presence of IgG, serum IgA, and secretory IgA antibodies capable of mediating ADCC may be critical in maintaining a functional immune response in all stages of HIV infection.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Adult Antibody-Dependent Cell Cytotoxicity/DRUG EFFECTS AIDS-Related Complex/IMMUNOLOGY Female Human HIV Infections/*BLOOD/IMMUNOLOGY HIV Seronegativity/IMMUNOLOGY HIV Seropositivity/BLOOD IgA, Secretory/BLOOD/*PHARMACOLOGY Immunoglobulins/IMMUNOLOGY Male Middle Age Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
970228
M9721896

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .